The acquisition of the Northampton, UK based company will expand Wasdell’s capacity in Britain at the company’s Newcastle-upon-Tyne facility to support the company’s increasing demand for outsourced pharmaceuticals.
Vincent Dunne, CEO of Wasdell said in a statement, “By increasing our capacity and service offerings here in the UK, we will be able better service our growing client base in the US as they look to Wasdell to provide a fully outsourced supply chain for their products within Europe.”
Martin Tedham, chairman of the Wasdell group said in a statement that Honeywood’s oral liquid manufacturing capabilities in particular, will allow Wasdell to increase capacity at its UK facility which demand calls for.
Dunne added the increased capacity offerings in the UK will enable the company to provide a fully outsourced supply chain in Europe. Along with a bolstered supply chain, Tedham said, “customers will benefit from expanded services, capacity, and continuity.”
Financial details of the deal have yet to been announced.